Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a hold rating in a report published on Saturday.

Several other equities research analysts also recently weighed in on VYGR. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. HC Wainwright lowered their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.12.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $3.93 on Friday. The company has a fifty day moving average of $4.55 and a two-hundred day moving average of $3.73. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $7.44. The company has a market capitalization of $218.51 million, a PE ratio of -1.82 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. The business had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. On average, research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares in the company, valued at approximately $591,926.52. This represents a 5.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $256,000. Nuveen LLC purchased a new stake in Voyager Therapeutics during the first quarter worth approximately $368,000. American Century Companies Inc. increased its position in shares of Voyager Therapeutics by 7.2% in the first quarter. American Century Companies Inc. now owns 131,521 shares of the company’s stock worth $445,000 after acquiring an additional 8,795 shares in the last quarter. Hsbc Holdings PLC raised its position in Voyager Therapeutics by 74.0% in the first quarter. Hsbc Holdings PLC now owns 67,903 shares of the company’s stock valued at $229,000 after purchasing an additional 28,878 shares during the period. Finally, CWM LLC raised its holdings in shares of Voyager Therapeutics by 856.3% during the 1st quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after buying an additional 9,376 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.